penn medicine
penn surgery
penn surgery home penn surgery clinical penn surgery education penn surgery research penn surgery administration

Jeffrey A. Drebin, M.D., Ph.D., F.A.C.S.
Gastrointestinal Surgery

 
  • Profile Home
  • Appointments
  • Education
  • Societies
  • Research
  • Publications
  • Awards

Administrative Office:
Hospital of the University of Pennsylvania
3400 Spruce Street
4 Silverstein Pavilion
Philadelphia, Pennsylvania 19104
Executive Assistants:
Denise Orr and Bobbie Hamilton
Administrative Telephone: 215-662-7539
Administrative Fax: 215-614-0363
Patient Appointments: 215-662-2626

Clinical Office:
Perelman Center for Advanced Medicine
GI Surgery
West Pavilion, 4th Floor
3400 Civic Center Boulevard
Philadelphia, PA 19104

Contact Information (internal use only)

jeffrey.drebin@uphs.upenn.edu

 

Jeffrey A. Drebin, MD, PhD, is Chair of the Department of Surgery at Penn Medicine, and the 14th John Rhea Barton Professor of Surgery at the Perelman School of Medicine. A tradition established in 1878, the Barton Professorship was the nation’s first endowed medical chair in any discipline. In his position, Dr. Drebin oversees a diverse range of programs and services spanning 11 divisions in the Department of Surgery, including advanced patients care, basic and clinical research and the surgical education program.

A graduate of Harvard Medical School, Dr. Drebin continued his surgical training at the Johns Hopkins University School of Medicine before joining the faculty at the Washington University School of Medicine in St. Louis. In 2004 he was recruited to the University of Pennsylvania School of Medicine as Professor, Chief of the Division of Gastrointestinal Surgery and vice-chairman for research for the Department of Surgery.  He became Department Chair and received the Barton Professorship in 2009.

Previously the William Maul Measey Professor in Surgical Research at Penn, Dr. Drebin’s research contributed significantly to our understanding of the genetic origins of cancer. His classic work with monoclonal antibodies directed against the HER2/neu protein provided the scientific foundation for the evolution of targeted therapeutics for cancer and the led to the development of the first generation of targeted monoclonal antibody drugs for the treatment of breast cancer. Dr. Drebin’s laboratory continues to explore new approaches to understanding the molecular biology of colon, liver and pancreatic cancers. Current research efforts are focused on novel approaches to the targeted therapy of these gastrointestinal malignancies.  His research has been supported by grants from multiple agencies, including the NIH, the Department of Defense and the Burroughs-Wellcome Fund.  He is currently the co-Principal Investigator on a $22 million dollar clinical and translational “dream team” award from the Stand Up to Cancer Foundation for innovative studies in pancreas cancer.

His many clinical interests include pancreatic cancer; acute and chronic pancreatitis; the use of new technologies to manage liver tumors; disorders of the bile ducts and management of gallbladder disease. Dr. Drebin has published more than 100 peer-reviewed research papers, book chapters and reviews, many of which help increase our understanding of the molecular biology of cancer, provide pre-clinical support for the development of novel treatments or address advances in clinical care of patients with gastrointestinal malignancies.  He is co-inventor on two patents related to the treatment of cancer with monoclonal antibodies.

Dr. Drebin has been recognized by many professional and scientific societies and has served on study sections and scientific review groups for the National Cancer Institute (NCI), the Department of Defense and other biomedical research organizations. He has served on multiple Editorial Boards.  He currently serves on the Board of Scientific Advisors of the NCI, is President-Elect of the Society of Surgical Oncology, President of the Philadelphia Academy of Surgery, and Past-President of the Society for Clinical Surgery, one of the oldest and most prestigious surgical societies in the nation. In 2013 Dr. Drebin was elected to the Institute of Medicine of the National Academy of Sciences.

 
Appointments
1994 - 1995 Instructor in Surgery, Section of Surgical Oncology
The Johns Hopkins University School of Medicine
Baltimore, Maryland
   
1995 - 1999 Assistant Professor of Surgery,
Section of Surgical Oncology (1995-1996)
Section of Hepatobiliary
Pancreatic and Gastrointestinal Surgery (1996-1999)
Washington University School of Medicine
St. Louis, Missouri
   
1999 - 2002 Associate Professor of Surgery
Section of Hepatobiliary
Pancreatic and Gastrointestinal Surgery
Washington University School of Medicine
St. Louis, Missouri
 
2002 - 2004 Professor of Surgery and
Molecular Biology & Pharmacology
Washington University School of Medicine
St. Louis, Missouri
   
2004 - present Professor of Surgery
Perelman School of Medicine
Philadelphia, Pennsylvania
   
2005 - present William Maul Measey Professor of Surgical Research
Perelman School of Medicine
Philadelphia, Pennsylvania
   
2009 - present John Rhea Barton Professor
Perelman School of Medicine
Philadelphia, Pennsylvania
 
Hospital and Administrative Appointments
1994 - 1995 Assistant Chief, Halsted Surgery Service
The Johns Hopkins Hospital
Baltimore, Maryland
   
1994 - 1995 Assistant Chief
The Johns Hopkins-Bayview Medical Center
Baltimore, Maryland
   
1995 - 2004 Attending Surgeon
Barnes-Jewish Hospital
St. Louis, Missouri
   
1995 - 1999 Attending Surgeon
St. Louis Regional Medical Center
St. Louis, Missouri
 
1995 - 2004 Attending Surgeon
The John Cochran Veterans Administration Hospital
St. Louis, Missouri
   
1995 - 2004 Member, Washington University
A.J. Siteman Cancer Center
St. Louis, Missouri
   
2004 - 2011 Chief, Division of Gastrointestinal Surgery
Hospital of the University of Pennsylvania
Philadelphia, Pennsylvania
   
2009 - present Chairman, Department of Surgery
Hospital of the University of Pennsylvania
Philadelphia, Pennsylvania
   
2011-present  

Physician in Orthopedics-Surgical Services, Philadelphia Veterans        
Affairs Medical Center, Philadelphia, Pennsylvania

 
Other Appointments
1995 - 2004 Member, Siteman Cancer Center, Washington University School of Medicine
St. Louis, Missouri
   
2004 - present Member, Abramson Cancer Center
Perelman School of Medicine
 
Education/Training
1975 - 1979

B.A. Oberlin College
Oberlin, OH

   
1979 - 1987 M.D. Harvard Medical School
Cambridge, Massachusetts
   
1981 - 1987 Ph.D. Harvard University
Cambridge, Massachusetts (Immunology)
 
Post-Graduate Training and Fellowship Appointments
1987 - 1988 Intern, Department of Surgery
The Johns Hopkins Hospital
Baltimore, Maryland
   
1988 - 1989 Junior Resident, Department of Surgery
The Johns Hopkins Hospital
Baltimore, Maryland
   
1989 - 1991 Oncology Research Fellow
The Johns Hopkins University School of Medicine
Baltimore, Maryland
 
1991 - 1993 Senior Resident, Department of Surgery
The Johns Hopkins Hospital
Baltimore, Maryland
   
1993 - 1994 Chief Resident, Department of Surgery
The Johns Hopkins Hospital
Baltimore, Maryland
   
1994 - 1995 Fellow in Surgical Oncology
Department of Surgery, The Johns Hopkins Hospital
Baltimore, Maryland
 
Memberships/Societies
National Societies
  • American College of Surgeons
  • American Hepato-Pancreato-Biliary Association
    • Scientific Program Committee, 2003-2007
  • American Surgical Association
    • Program Committee, 2012-present
  • Association of Academic Surgeons
    • Membership Committee, 1999-2000
  • Halsted Society
  • Society for Surgery of the Alimentary Tract
    • Publications Committee, 2007-present
  • Society of Clinical Surgery
    • Admissions Committee, 2002-2004
    • Secretary, 2004-2008
    • President-Elect, 2008
    • President, 2010-2012
    • Past President, 2012-present
  • Society of Surgical Oncology
    • Councilor-at-large, Executive Council, 2003-2006
    • Scientific Program Committee, 2001-2004
      • Vice-Chairman, 2002-2003
      • Chairman, 2003-2004
    • Secretary, 2010-present
    • Chair, Membership Committee, 2010-present
    • Chair, Research, Policy and Practice Council, 2011-present
    • Administrative Council, 2011-present
    • President-Elect, 2014-present
  • Society of University Surgeons
  • Surgical Biology Club II
Regional and Local Societies
  • Philadelphia Academy of Surgery
    • Councilor-at-Large, 2009-present
    • Vice President, 2012
    • President Elect, 2013-2014
    • President, 2014-present
  • Saint Louis Surgical Society (inactive status 2004)
National Scientific Committees
  • American Association for Cancer Research
  • Pancreatic Cancer Research Grants Scientific Review Committee 2012-2013
  • American Board of Surgery, Associate Examiner, 2003, 2006, 2008, 2010
  • American College of Surgeons Commission on Cancer
    • Chairman, Pancreatic Cancer Disease Site Committee, 2002-2009
  • American College of Surgeons Oncology Group:
    • Gastric, Hepatobiliary and Pancreatic Subcommittee, 2000-2002
    • GI Cancer Subcommittee, 2003 - 2009
    • Executive Committee, 2004 - 2010
  • Department of Defense/U.S. Congressionally Directed Breast Cancer Research Program
    • Immunological Sciences 2 study section, 1999-2002
    • Clinical and Translational Research study section, 2000
  • G.M. Cancer Research Foundation, Kettering Prize Committee, 2001-2003
  • National Cancer Institute Pancreatic Cancer Progress Review Group, 1998
  • National Cancer Institute Board of Scientific Advisors, 2009-present
  • National Institutes of Health, Center for Scientific Reviews
    • Member, NCI Subcommittee-I study section, 2004-2008
    • Ad Hoc Member, NCI Molecular Carcinogenesis study section – Special Emphasis Panel, 2007
  • NIH Director’s Blue Ribbon Panel on Intramural Clinical Research, 2003
 
Gastrointestinal Surgical Research
Advances in our understanding of cancer biology have demonstrated that malignant cells arise as a result of the sequential accumulation of mutations that alter the function of growth regulatory genes. Dr. Drebin's research efforts are focused on developing approaches that target and disrupt the activity of proteins encoded by these growth regulatory genes or of downstream elements of signal transduction pathways they control. These studies serve both to increase our understanding of the molecular biology of cancer and provide pre-clinical support for the development of novel treatments. These studies are thus “translational” serving to bridge basic and clinical cancer research. Current Laboratory Projects Include:
 
Studies of ß-catenin in colon carcinoma
  • Defining the role of transcriptional regulation of ß-catenin in colon cancer
  • Development of novel agents to target ß-catenin in cancer cells
  • Evaluating the chemopreventative activity of ß-catenin targeted therapies in animal models of intestinal polyposis
  • Differentiating the contributions of ß- and gamma- catenin isoforms in stimulating cancer cell growth
Studies of HER2/neu in pancreatic carcinoma
  • Defining molecular events downstream of HER2/neu that drive pancreas cancer growth
  • Evaluating novel approaches to targeting HER2/neu in pancreatic cancer
  • Developing a pancreas-specific HER2/neu transgenic mouse model
 
Research Publications, Peer Reviewed
  1. Lowy A, Tominaga A, Drebin JA, Takeoki M, Benacerraf B, Greene MI.  Identification of an I-J + antigen presenting cell required for third-order suppressor T cell activation.  Journal of Experimental Medicine 157(1):353-358, Jan. 1, 1983.
  2. Drebin JA, Waltenbaugh C, Schatten S, Benacerraf B, Greene MI.  Inhibition of tumor growth by monoclonal anti-I-J antibodies.  Journal of Immunology 130(1):506-509, Jan. 1983.
  3. Carter R, Drebin JA, Schatten S, Perry LL, Greene MI.  Regulation of the immune response to tumor antigens IX. in vitro Ly 1+2– cell proliferative responses to cell bound or subcellular tumor antigen.  Journal of Immunology 130(2):997-1002, Feb. 1983.
  4. Lowy A, Flood P, Tominaga A, Drebin JA, Dambrauskas JT, Gershon RK, Greene MI.  Analysis of hapten specific T suppressor factors: Genetic restriction of TsF1 activity analyzed with synthetic hybrid suppressor factors.  Journal of Immunology 132(2):640-643, Feb. 1984.
  5. Lowy A, Drebin JA, Monroe JG, Granstein RD, Greene MI.  Genetically restricted antigen presentation for immunologic tolerance and suppression.  Nature 308(5957):373-375, Mar. 22-28, 1984.
  6. Schatten S, Drebin JA, Perry LL, Chung WC, Greene MI.  Regulation of the immune response to tumor antigens X. activation of third-order suppressor T cells that abrogate anti-tumor immune responses.  Journal of Immunology 133(2):1064-1069, Aug. 1984.
  7. Drebin JA, Schatten S, Greene MI.  The role of antigen presenting cells in regulating the im-mune response to tumor antigens.  Transplantation Proceedings 16(5):1377-1379, Oct. 1984.
  8. Schechter AL, Stern DF, Vaidyanathan L, Decker SJ, Drebin JA, Greene MI, Weinberg RA.  The neu oncogene: An erbB related oncogene that encodes a 185,000 Mr tumor antigen.  Nature 312(5994):513-516, Dec. 6-12, 1984.
  9. Drebin JA, Stern DF, Link VC, Weinberg RA, Greene MI.  Monoclonal antibodies identify a cell surface antigen associated with an activated cellular oncogene.  Nature 312(5994):545-548, Dec. 6-12, 1984.
  10. Drebin JA, Link VC, Stern DF, Weinberg RA, Greene MI.  Down-modulation of an oncogene protein product and reversion of the transformed phenotype by monoclonal antibodies.  Cell 41(3):695-706, July 1985.
  11. Drebin JA, Link VC, Weinberg RA, Greene MI.  Inhibition of tumor growth by a monoclonal antibody reactive with an oncogene-encoded tumor antigenProceedings of the National Academy of Sciences (USA) 83(23):9129-9133, Dec. 1986.
  12. Bruck C, Drebin JA, Glineur C, Portetelle D.  Purification of mouse monoclonal antibodies from ascitic fluid by DEAE affi-gel blue chromatographyMethods in Enzymology 121:587-596, 1986.
  13. Kokai Y, Cohen JA, Drebin JA, Greene MI.  Stage and tissue-specific expression of the neu oncogene in rat development.  Proceedings of the National Academy of Sciences (USA) 84(23):8498-8501, Dec. 1987.
  14. Drebin JA, Link VC, Greene MI.   Monoclonal antibodies reactive with distinct domains of the neu oncogene-encoded p185 molecule exert synergistic anti-tumor effects in vivoOncogene 2(3):273-277, Mar. 1988.
  15. Drebin JA, Link VC, Greene MI.   Monoclonal antibodies specific for the neu oncogene product directly mediate anti-tumor effects in vivoOncogene 2(4):387-394, Apr. 1988.
  16. Myers JN, Drebin JA, Greene MI.  Biological effects of monoclonal anti-receptor antibodies reactive with the neu oncogene product, p185neu.  Methods in Enzymology 198:277-290, 1991.
  17. Drebin JA, Hartzell SW, Griffen C, Campbell MJ, Niederhuber JE.  Molecular cloning and chromosomal localization of the human homologue of a B lymphocyte-specific protein tyrosine kinase gene, blkOncogene 10(3):477-486, Feb. 2, 1995.
  18. Katsumata M, Okudaira T, Clark D, Drebin JA, Jolicoeur P, Greene MI.  Prevention of breast tumour development in vivo by down regulation of the p185neu receptor.  Nature Medicine 1(7):644-648, July 1995.
  19. Roh H, Pippen J, Drebin JA.  Her2/neu-specific antisense oligonucleotides inhibit the growth if human pancreatic carcinoma cells that over express the HER2/neu oncogene.  Surgical Forum 48: 852-855, 1997.
  20. Qian X, O’Roarke DM, Drebin JA, Zhao H, Wang Q, Greene MI.  Identification of p185neu sequences required for monoclonal antibody- or ligand-mediated receptor signal attenuation.  DNA and Cell Biology 16(12):1395-1405, Dec. 1997.
  21. Roh H, Pippin J, Boswell CB, Drebin JA.  Antisense oligonucleotides specific for the HER2/neu oncogene inhibit the growth of human breast carcinoma cells that over express HER2/neu.  Journal of Surgical Research 77(1):85-90, June 1998.
  22. Boswell CB, Pippen J, Drebin JA.  Down regulation of HER2/neu expression using combinations of antisense oligonucleotides and monoclonal antibodies results in enhanced antitumor effects.  Surgical Forum 49: 456-458, 1998.
  23. Roh H, Boswell C, Hirose C, Pippin J, Drebin JA.  Synergistic anti-tumor effects of HER2/neu antisense oligodeoxynucleotides and conventional chemotherapeutic agents.  Surgery 126(2):413-421, Aug. 1999.
  24. Zhang H, Wang Q, Montone KT, Peavey JE, Drebin JA, Greene MI, Murali R.  Shared antigenic epitopes and pathobiological functions of anti-p185HER2/neu monoclonal antibodies.  Experimental and Molecular Pathology 67(1):15-25, Sept. 1999.
  25. Strasberg SM, Middleton WD, Teefey SA, McNevin MS, Drebin JA.  Management of diagnostic dilemmas of the pancreas by ultrasound-guided laparoscopic biopsy.  Surgery 126(4):736-743, Oct. 1999.
  26. Roh H, Pippin J, Drebin JA.  Down-regulation of HER2/neu expression induces apoptosis in human cancer cells that over express HER2/neu.  Cancer Research 60(3):650-655, Feb. 1, 2000.
  27. Worrall NK, Drebin JA.  Pancreaticoduodenectomy for lymphoepithelial cyst of the pancreas.  American Surgeon 66(8):732-734, Aug. 2000.
  28. Strasberg SM, Eagon CE, Drebin JA.  Hidden cystic duct syndrome and the infundibular technique of laparoscopic cholecystectomy: The danger of the false infundibulum.  Journal of the American College of Surgeons 191(6):661-667, Dec. 2000.
  29. Roh H, Pippin JA, Green DW, Boswell CB, Hirose C, Mokadam NA, Drebin JA.  HER2/neu antisense targeting of human breast carcinoma.  Oncogene 19(53):6138-6143, Dec. 11, 2000.
  30. Mokudam NA, Roh H, Pippen J, Green DW, Drebin JA.  A bifunctional antisense oligonucleotide targeting a region of sequence homology simultaneously down regulates both β and γ catenin expression in colorectal carcinoma cells.  Surgical Forum 52: 281-284, 2001.
  31. Strasberg SM, Dehdashti F, Siegel BA, Drebin JA, Linehan D.  Survival of patients evaluated by FDG-PET before hepatic resection for metastatic colorectal carcinoma: a prospective database study.  Annals of Surgery 233(3):293-299, Mar. 2001.
  32. Strasberg SM, Picus DD, Drebin JA.  Results of a new strategy for reconstruction of biliary injuries having an isolated right sided component.  Journal of Gastrointestinal Surgery 5(3):266-274, May/June 2001.
  33. Roh H, Green DW, Boswell CB, Pippin JA, Drebin JA.  Suppression of beta-catenin inhibits the neoplastic growth of APC-mutant colon cancer cells.  Cancer Research 61(17):6563-6568, Sept. 1, 2001.
  34. Green DW, Roh H, Pippin JA, Drebin JA.  b-catenin antisense treatment decreases b-catenin expression and tumor growth rate in colon carcinoma xenografts.  Journal of Surgical Research 101(1):16-20, Nov. 2001.
  35. Vollmer C, Drebin JA, Middleton WD, Teefey SA, Linehan D, Soper NJ, Eagon CJ, Strasberg SM.  Utility of staging laparoscopy in subsets of peripancreatic and biliary malignancies.  Annals of Surgery 235(1):1-7, Jan. 2002.
  36. Strasberg SM, Drebin JA, Mokadam NA, Green DW, Jones K, Ehlos J, Linehan DC.  Prospective trial of a blood supply based technique of pancreaticojejunostomy: effect on anastomotic failure in the Whipple procedure.  Journal of the American College of Surgeons 194(6):746-758, June 2002.
  37. Strasberg SM, Drebin JA, Linehan DC.  Use of a bipolar vessel sealing device for parenchymal transection during liver surgery.  Journal of Gastrointestinal Surgery 6(4):569-574, July/Aug. 2002.
  38. Liyanage UK, Moore TT, Joo H-G, Tanaka Y, Herrmann V, Doherty G, Drebin JA, Strasberg SM, Eberlein TJ, Goedegebuure PS, Linehan DC.  Prevalence of regulatory T cells is increased in peripheral blood and tumor microenvironment of patients with pancreas and breast adenocarcinoma.  Journal of Immunology 169(5):2756-2761, Sept. 1, 2002.
  39. Winslow ER, Brunt LM, Drebin JA, Soper NJ, Klingensmith ME.  Portal vein thrombosis after splenectomy.  American Journal of Surgery 184(6):631-635, Dec. 2002.
  40. Strasberg SM, Drebin JA, Linehan D.  Radical antegrade modular pancreato-splenectomy.  Surgery 133(5):521-527, May 2003.
  41. Veeramachaneni N, Kubokura H, Lin L, Pippin J, Patterson A, Drebin JA, Battafarano R.  Down-regulation of beta-catenin inhibits the growth of squamous esophageal carcinoma cells.  Journal of Thoracic and Cardiovascular Surgery 127(1):92-8, 2004 Jan.).
  42. Fernandez FG, Drebin JA, Linehan DC, Dehdashti F, Siegel BA, Strasberg SM.  Five-year survival after resection of hepatic metastases from colorectal cancer in patients screened by positron emission tomography with F-18 fluorodeoxyglucose (FDG-PET). Annals of Surgery 240(3):438-450, Sept. 2004.
  43. Lin LL, Picus J, Drebin JA, Linehan DC, Solis J, Strasberg SM, Tan B, Thorstad WL, Myerson R.  A phase II study of alternating cycles of split course radiation therapy and gemcitabine chemotherapy for inoperable pancreatic or biliary tract carcinoma.  American Journal of Clinical Oncology 28(3):234-241, June 2005.
  44. Canter RJ, Kesmodel SB, Heitjan DF, Veeramachaneni NK, Mokadam NA, Drebin JA, Fraker DL.  Suppression of beta-catenin by antisense oligomers augments tumor response to isolated limb perfusion in a rodent model of adenomatous polyposis coli-mutant colon cancer.  Annals of Surgical Oncology 12(9):733-742, Sept. 2005.
  45. Lee CJ, Scheiman J, Anderson MA, Hines OJ, Reber HA, Farrell J, Kochman ML,  Foley, PJ, Drebin J, Oh YS, Ginsberg G, Ahmad N, Merchant NB, Isbell J, Parikh AA, Stokes JB, Bauer T, Adams RB, Simeone DM.  Risk of malignancy in resected cystic tumors of the pancreas </= 3 cm in size: is it safe to observe asymptomatic patients? A multiinstitutional report.  Journal of Gastrointestinal Surgery 12:234-242, 2008.
  46. Cai Z, Zhang G, Zhou Z, Bembas K, Drebin JA, Greene MI, Zhang H Differential binding patterns of monoclonal antibody 2C4 to the ErbB3-p185her2/neu and the EGFR- p185her2/neu complexes.  Oncogene 27:3870-3874, 2008.
  47. Foley PJ, Scheri RP, Smolock CJ, Green DW, Pippin JA, Drebin, JA.  Targeted suppression of β-catenin blocks intestinal adenoma formation in apc min mice.  Journal of Gastrointestinal Surgery 12:1452-1458, 2008.
  48. Linehan DC, Tan MCB, Strasberg SM, Drebin JA, Hawkins WG, Picus J, Myerson RJ, Malayapa RS, Hull M, Trinkaus K, Tan, BR. Adjuvant interferon-based chemoradiation followed by gemcitabine for resected pancreatic adenocarcinoma: a single institution phase II study.  Annals of Surgery 248:145-151, 2008.
  49. Freudenberg JA, Wang Q, Katsumata M, Drebin J, Nagatomo I, Greene MI. The role of HER2 in early breast cancer metastasis and the origins of resistance to HER2-targeted therapies. Exp Mol Pathol. 2009 Aug;87(1):1-11. Epub 2009 May 18.
  50. Kelz  RR, Mullen  JL, Kaiser LR, Pray  LA,  Shea GP, Drebin JA, Wirtalla CJ, Morris JB:   Prevention of surgical resident attrition by a novel selection strategy. Annals of Surgery 252: 537-543, 2010.
  51. Reinke CE, Drebin JA, Kreider S, Resnick A, Raper S, Kelz RR:  Timing of pre-operative pharmacoprophylaxis for pancreatic surgery patients: a venous thromboembolism reduction initiative.  Annals of Surgical Oncology 19(1):19-25, Jan. 2012.
  52. Sohal D, Metz J, Sun W, Harlacker K, Giantonio B, Ginsberg G, Kochman M, Teitelbaum U, Redlinger C, Heitjan D, Feldman M, Drebin J, O’Dwyer P. Toxicity Study Of Gemcitabine, Oxaliplatin And Bevacizumab, Followed By 5-Fluorouracil, Oxaliplatin, Bevacizumab And Radiotherapy, In Patients With Locally Advanced Pancreatic Cancer. Cancer (submitted for publication).
  53. Apisarnthanarax S, Christensen VC, Guo M, Claghorn KVB, Hampshire M, Sun W, Drebin, JA, Plastaras JP, Metz JM. Aggressive Supportive Care Improves Outcomes in the Combined Modality Treatment of Pancreatic and Duodenal Cancer. Journal of Clinical Oncology (submitted for publication).
  54. Datta J, Shafi BM, Drebin JA. Extrahepatic cholangiocarcinoma developing in the setting of AIDS cholangiopathy. The American Surgeon: Brief Report (in press).
  55. Shinohara ET, Kassaee A, Mitra N, Vapiwala N, Plastaras JP, Drebin JA, Wan F, Metz JM: Feasibility of the use of electromagnetic transponders to monitor inter and intra-fractional motion in locally advanced pancreatic cancer patients.  International Journal of Radiation Oncology, Biology, Physics 83(2):566-73. June 2012.
  56. Reinke CE, Karakousis GC, Hadler RA, Drebin JA, Fraker DL, Kelz RR. Incidence of venous thromboembolism in patients undergoing surgical treatment for malignancy by type of neoplasm: An analysis of ACS-NSQIP data from 2005 to 2010. Surgery, 2012 Aug;152(2):186-92.
  57. Singla S, Pippin J, Drebin JA. Dual ErbB1 and ErbB2 receptor tyrosine kinase inhibition exerts synergistic effect with conventional chemotherapy in pancreatic cancer. Oncology Reports 28(6):2211-6. Dec 2012. Epub 2012 Sep 24.
  58. Lewis R, Drebin JA, Callery M, Fraker D, Kent T, Gates J, Vollmer C.   A Contemporary Analysis of Survival for Resected Pancreatic Ductal Adenocarcinoma. HPB 2013 Jan; 15(1): 49-60. Epub 2012 Sep 24.
Reviews in Peer-Reviewed Research Publications
  1. Drebin JA, Perry LL, Carter R, Greene MI. Regulation of the immune response to antigens on the malignant cell surface. Seminars in Immunopathology 5(2):75-192, 1982.
  2. Schatten S, Granstein RD, Drebin JA, Greene MI. Suppressor T cells and the immune response to tumors. Critical Reviews in Immunology 4(4): 335-379, 1984.
  3. Schatten S, Drebin JA, Granstein R, Greene MI. Differential antigen presentation in tumor immunity. Federation Proceedings 43(9):2360-2364, June 1984.
  4. Strasberg SM, Drebin JA, Soper NJ. Evolution and current status of the Whipple procedure. Gastroenterology 113(3):983-994, Sept. 1997.
  5. Green DW, Roh H, Pippin JA, Drebin JA. Antisense oligonucleotides: an evolving technology for the modulation of gene expression in human disease. Journal of the American College of Surgeons 191(1):93-105, July 2000.
  6. Zhang H, Berezov A, Wang Q, Zhang G, Drebin J, Murali R, Greene MI. ErbB receptors: From oncogenes to targeted cancer therapies. Journal of Clinical Investigation 117(8):2051-2058, Aug. 2007.
Abstracts (last 3 years)
  1. Hoffman RL, Gates JL, Ahmad NA, Ginsberg GG, Kochman ML, Drebin JA. Validation of Consensus Panel Guidelines for the Management of Pancreatic Cystic Neoplasms. 64th Annual Cancer Symposium of the Society of Surgical Oncology, Abstract # P196, 2011.
  2. Sohal D, Metz JM, Sun W, Harlacker K, Giantonio BJ, Rosato EF, Ginsberg G,  Kochman M, Teitelbaum UR, Redlinger C, Feldman MD, Drebin JA, O'Dwyer PJ. Toxicity study of gemcitabine, oxaliplatin, and bevacizumab followed by 5-fluorouracil, oxaliplatin, bevacizumab, and radiotherapy in patients with locally advanced pancreatic cancer. Gastrointestinal Cancers Symposium, Abstract # 337, 2012.
  3. Lewis R, Drebin JA, Callery MP, Fraker DF, Kent TS, Gates JL, Vollmer CM.  Dissecting Survival for Resected Pancreatic Ductal Adenocarcinoma (PDAC) in the Contemporary Era. 12th Annual Americas Hepato-Pancreato-Biliary Congress, Abstract #45, 2012.
  4. Lewis R, Drebin JA, Callery MP, Fraker DF, Kent TS, Gates JL, Vollmer CM.  Failure to Receive Adjuvant Therapy Following Resection for Pancreatic Cancer: Patterns and Implications. 53rd Annual Meeting, The Society for Surgery of the Alimentary Tract, Abstract #Su1547, 2012.
  5. Lewis R, Drebin JA, Callery MP, Fraker DF, Kent TS, Gates JL, Vollmer CM. Extending The Criteria For Surgery On “Unresectable” Pancreatic Cancer. 10th World Congress of the International Hepato-Pancreato-Biliary Association, Abstract #238, 2012.
  6. Vollmer CM, Lewis R, Callery MP, Fraker D, Gates J, and Drebin JA. Resected Pancreatic Ductal Adenocarcinoma (PDAC) With Favorable Prognosis: Is Adjuvant Therapy Beneficial? 8th Annual Academic Surgical Congress,Abstract #26.7, 2013.
  7. Miller B, Christein JD, Callery MP, Kent TS, Pratt W, Drebin JA, and Vollmer CM. Assessing the Impact of Fistulas After Pancreaticoduodenectomy Using the Postoperative Morbidity Index (PMI). 13th Annual Americas Hepato-Pancreato-Biliary Congress, 2013.
  8. Miller B, Christein JD, Behrman S, Drebin JA, Pratt WB, Callery MP, and Vollmer CM. A Multicenter External Validation of the Fistula Risk Score for Pancreatoduodenectomy. Accepted for the Society for Surgery of the Alimentary Tract 54nd Annualmeeting for Digestive Disease Week and to the Pancreas Club 47th Annual Meeting. Orlando, FL. May 2013.
Editorials, Chapters & Participation in Committee Reports
  1. Drebin JA, Perry LL, Bromberg JS, Nepom J, Benacerraf B, Greene MI. The effects of antisera directed at I-region gene products on syngeneic tumor immunity. In: Immuno-chemotherapy. Nydegger UE, ed. New York: Academic Press, 1981, 99-108.
  2. Drebin JA, Shilo BZ, Weinberg RA, Greene MI. Preliminary evidence of an
    association between an activated cellular transforming gene and a tumor-specific transplantation antigen. In: B and T Cell Tumors. Vitetta E, Fox CF, eds. New York: Academic Press, 1982, 221-226.
  3. Schatten S, Drebin JA, Takeoki M, Carter R, Tominaga A, Abbas A, Finberg R, Greene MI. Regulation of the immune response to cell surface antigens. In: B and T Cell Tumors. Vitetta E, Fox CF, eds. New York: Academic Press, 1982, 349-368.
  4. Lowy A, Tominaga A, Drebin JA, Benacerraf B, Greene MI. Activation of
    suppressor cells is genetically restricted by the I-J subregion. In: Ir Genes: Past, Present and Future. Pierce CW, Cullen SE, Kapp JA, Schwartz BD, Shreffler DC, eds. Clifton, NJ: The Humana Press, 1983, 515-520.
  5. Drebin JA, Schatten S, Tominaga A, Lefort S, Letvin NL, Bast RC, Mizel S, Greene MI. Characterization of ultraviolet radiation-induced impairment of antigen presenting cell function at the cellular and molecular level. In: The Effects of Ultraviolet Radiation on the Immune System. Parrish J, ed. Skillman, NJ: Johnson & Johnson Press, 1983, 123-142.
  6. Drebin JA, Link VC, Stern DF, Weinberg RA, Greene MI. Immune responses against transforming gene associated antigens. In: Regulation of the Immune System. Sercarz E, Cantor H, Chess L, eds. New York: Alan R. Liss, Inc., 1984, 919-928.
  7. Stern DF, Schechter A, Vaidyanathan L, Weinberg R, Greene M, Drebin J. The neu oncogene encodes a cell surface protein with properties of a growth factor receptor. In: Genetics, Cell Differentiation, and Cancer. Marks PA, ed. New York: Academic Press, 1985, 165-170.
  8. Drebin JA, Link VC, Stern DF, Weinberg RA, Greene MI. Development of
    monoclonal antibodies reactive with the product of the neu oncogene. In: Immunology and Cancer. Kripke M, ed. Austin, TX: University of Texas Press, 1986, 277-289.
  9. Drebin JA, Link VC, Greene MI. Monoclonal antibodies reactive with the neu
    oncogene product inhibit the neoplastic properties of the neu-transformed cells. In: Development and Recognition of the Transformed Cell. Greene MI, Hamaoka T, eds. New York: Plenum Press, 1987, 69-80.
  10. Drebin JA, Hartzell SW, Niederhuber JE. Recombinant DNA technology. In: Principles and Practices of Surgical Research. Troidl H, Spitzer WO, McPeek B, Mulder DS, McKneally MF, Wechsler AS, Balch CM, eds. New York: Springer-Verlag, 1991, 342-353.
  11. Drebin JA, Hartzell SW, Niederhuber JE. Tumor markers in cancer diagnosis and therapy. In: Current Therapy in Oncology. Niederhuber J, ed. Philadelphia: BC Decker, Inc., 1992, 58-61.
  12. Drebin JA, Niederhuber JE. Colon cancer. In: Current Therapy in Oncology.
    Niederhuber J, ed. Philadelphia: BC Decker, Inc., 1992, 426-431.
  13. Drebin JA, Mundy LM. The management of postoperative wound infections. In: Current Surgical Therapy, 6th Edition. Cameron J, ed. Philadelphia: Mosby-Year Book, 1998, 1078-1082.
  14. Strasberg SM, Drebin JA. Tumors of the biliary tree. In: Textbook of
    Gastroenterology, 3rd Edition. Yamada T, ed. Philadelphia: Lippincott-Raven, Inc., 1999, 2326-2342.
  15. Drebin JA, Strasberg SM. Pancreatic carcinoma and tumors of the peri-ampullary region. In: Cancer Surgery for the General Surgeon. Winchester DP, Daly JM, Jones RS, Murphy GP, eds. Philadelphia: Lippincott-Raven, Inc., 1999, 195-211.
  16. Chi D, Drebin JA. The pancreas. In: The Washington Manual of Surgery, 2nd Edition. Doherty GM, Meko J, Peplinski G, Olson J, Worrall N, eds.Philadelphia: Lippincott, Williams and Wilkins, 1999, 259-272.
  17. Strasberg S, Drebin J. Calculous biliary disease. Chap. 41 in: Surgery: Scientific Principles and Practice. Greenfield LJ, Mulholland MW, Oldham KT, Zelenock GB, Lillimoe KD, eds. Philadelphia: Lippincott, Williams and Wilkins, 2001, 9-31.
  18. Green DW, Drebin JA. Cancer genetics. In: Surgical Research. Souba W, Wilmore D, eds. San Diego: Academic Press, 2001, 445-456.
  19. Drebin JA, Strasberg SM. Technical aspects of biliary and pancreatic reconstruction after pancreaticoduodenectomy. In: Pancreatic Cancer. Evans D, Pisters PWT, Abbruzzese A, eds. New York: Springer-Verlag, Inc., 2002, 171-180.
  20. Amos K, Drebin JA. The pancreas. In: The Washington Manual of Surgery, 3rd Edition. Doherty GM, Lowney GK, Mason JE, Reznick SI, Smith MA, eds.
    Philadelphia: Lippincott, Williams and Wilkins, 2002, 293-306.
  21. Drebin JA, Strasberg SM. Tumors of the biliary tree. In: Textbook of
    Gastroenterology, 4th Edition. Yamada T, editor. Philadelphia: Lippincott-Raven, Inc., 2003, 2234-2251.
  22. Scheri R, Drebin JA. Tumors of the small intestine. In: Current Surgical Therapy, 9th Edition. Cameron J, editor. Philadelphia: Mosby-Year Book, Inc., 2004, 120-124.
  23. Drebin JA. Carcinoma of the pancreas. In: Clinical Oncology, 3rd edition. (Abeloff MD, Armitage JO, Niederhuber JE, Kastan MB, McKenna WG, editors. London: Churchill Livingstone, Inc., 2004, 2015-2033.
  24. Sun WJ, Morris JB, Drebin JA. Medical and surgical therapy of pancreaticobiliary malignancies. In: Endoscopic Oncology: Gastrointestinal Endoscopy and Cancer Management. Faigel DO, Kochman ML, editors. Totawa, NJ: Humana Press, 2006, 353-363.
  25. Kesmodel S, Drebin JA. Tumor biology. In: The Surgical Review: An Integrated Basic and Clinical Science Study Guide, 2nd edition. Atluri, P, Karakousis, G, Porrett, P, Kaiser, L, editors. Philadelphia: Lippincott, Williams and Wilkins, 2006, 61-84.
  26. Katsumata M, Drebin JA, Greene MI. Trastuzumab in breast cancer. [commentary] New England Journal of Medicine 354(6):640-644, Feb. 9, 2006.
  27. Smolock CJ, Drebin JA. Tumors of the biliary tree. In: Textbook of Gastroenterology, 5th Edition. Yamada, T, editor. Oxford, UK: Blackwell Publishing, 2008 (in press).
  28. Drebin, JA, Sun, WJ, Metz, J, Furth, E. Carcinoma of the pancreas. In: Clinical Oncology, 4th edition. Abeloff, MD, Armitage, JO, Niederhuber, JE, Kastan, MB, McKenna, WG, editors. London: Churchill Livingstone, Inc., 2008, 1595-1612.
  29. Gates, J, Drebin, J.A. Abdominal masses. In: Clinician’s Guide to Surgical Care. Pryor, J, Todd, B, Dryer M, editors. New York: McGraw-Hill, Inc., 2008, 225-240.
  30. Resnick, AS, Drebin, JA. Distal pancreatectomy. In: Pancreatic Cancer. Lowy, A, Leach, S, Philip, P, editors. New York: Springer-Verlag, 2008 (in press).
  31. Foley PJ, Drebin JA. Pancreatic resection. In: Gowned and Gloved Surgery:
    Introduction to Common Procedures. Roses RE, Paulson EC, Kanchwala S, editors. Philadelphia: Elsevier, Inc. 2008 (in press).
  32. Drebin, JA. Pancreatic cystic neoplasms – why not operate? [editorial]
    Gastrointestinal Endoscopy, 2009, 821-823.
Patents
  1. Greene MI, Drebin JA, inventors. Treatment of tumors with monoclonal antibodies against oncogene antigens. U.S. Patent #5824311, awarded 10/20/98. This patent has been licensed to Genentech, Inc. by the University of Pennsylvania.
  2. Greene MI, Katsumata M, Drebin J, inventors. Prevention of tumors with monoclonal antibodies against neu. U.S. Patent Application #20040202664.
 
Awards, Honors and Membership in Honorary Societies:
1979 Phi Beta Kappa
 
1979 Sigma Xi
 
1979 B.A. with Highest Honors, Oberlin College
 
1981  Medical Scientist Training Program Fellowship, NIH
 
1984 R. Gershon Memorial Fellowship, Cancer Research Institute
 
1985 W. S. Stone Memorial Award, M.D. Anderson Tumor Institute
 
1987 Henry A. Christian Award, Harvard Medical School
 
1987 M.D. Magna cum Laude, Harvard Medical School
 
1990 George D. Zuidema Research Award, Johns Hopkins University
 
1994  Alpha Omega Alpha
 
1996 American College of Surgeons Faculty Research Fellowship
 
1998 Society for Surgery of the Alimentary Tract Career Development Award
 
1998 Everts A. Graham Resident Teaching Award, Washington University
 
1998 Fellow, American College of Surgeons
 
1998 Caring Spirit Award, Barnes-Jewish Hospital
 
2001  Burroughs Wellcome Clinician Scientist Award in Translational Research
 
2002 Elected Councilor-at-Large, Society of Surgical Oncology
 
2005 William Maul Measey Chair in Surgical Research
Perelman School of Medicine at the University of Pennsylvania
   
2007 Listed in Philadelphia Magazine “Top Doctors”; Castle  Connolly, “America’s Top Doctors”;
and Best Doctors in America, Inc “Best Doctors”
 
2008 Listed in Philadelphia Magazine “Top Doctors”; Castle Connolly, “America’s Top Doctors”, “America’s Top Doctors for Cancer”; and Consumers’ Research Council “America’s Top Surgeons”
 
2009 Listed in Philadelphia Magazine “Top Doctors”; Castle Connolly, “America’s Top Doctors”; Best Doctors in America, Inc “Best Doctors”; and Consumers’ Research Council “America’s Top Surgeons”
 
2009 The John Rhea Barton Professor, Department of Surgery
Perelman School of Medicine at the University of Pennsylvania
 
2009 Louis Duhring Outstanding Clinical Specialist Award, Perelman                                
School of Medicine at the University of Pennsylvania
 
2010 Listed in Philadelphia Magazine “Top Doctors”; Castle Connolly, “America’s Top Doctors”; Best Doctors in America, Inc. “Best Doctors”; Consumers’ Research Council “America’s Top Surgeons”
 
2011 Listed in Philadelphia Magazine “Top Doctors”; Castle Connolly, “America’s Top Doctors”; Best Doctors in America, Inc. “Best Doctors”; Consumers’ Research Council “America’s Top Surgeons”
 
2012 Listed in Philadelphia Magazine “Top Doctors”; Castle Connolly, “America’s Top Doctors”; Best Doctors in America, Inc. “Best Doctors”; Consumers’ Research Council “America’s Top Surgeons”
 
2013 Listed in Philadelphia Magazine “Top Doctors”; Castle Connolly, “America’s Top Doctors”; Best Doctors in America, Inc. “Best Doctors”; Consumers’ Research Council “America’s Top Surgeons”
   
2013 The Gordon P. Buzby Surgical Leadership Award

Dr. Drebin

 
footer Terms of Use Legal Disclaimer Site Map Contact Us Financial Assistance About Penn Medicine Privacy Statement
penn medicine